Jefferies initiates Mentari Therapeutics stock with buy rating on migraine pipeline
Jefferies initiated coverage on Mentari Therapeutics (NASDAQ:MTRI) with a buy rating and a $30.00 price target, citing its migraine prevention drug pipeline. The stock trades at $16, 31% below its 52-week high. The company expects Phase I data for MT-001 and MT-002 in 2027. MTRI has $450 million in cash, providing runway into 2029.
How this was made
The 30-second read
Why it matters
The new coverage could trigger a short‑term rally, but long‑term performance hinges on trial outcomes.
Market read
Analyst initiation provides fresh actionable insight for traders.
What to watch
Cash runway is strong, but valuation assumes successful later‑stage trials.
Background
Mentari Therapeutics is a small‑cap biotech developing PACAP‑based migraine preventatives.
Ticker impact
Jefferies initiates coverage on Mentari Therapeutics with a buy rating and a $30 price target, highlighting its migraine pipeline.
upward pressure as investors price in the new buy rating and target.
The initiation of coverage with a buy rating is a fresh catalyst that can attract new capital into the stock.
Market effects
May lift sentiment in the biotech migraine‑therapy niche.
Limited to US biotech investors.
Minor, confined to niche therapeutic area.
Counterpoint
The pipeline is early‑stage; investors may remain cautious until Phase II data.
Key entities
- AnalystJefferies
Initiated coverage with a buy rating.
- CompanyMentari Therapeutics
Biotech developing migraine treatments.

